Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00784875 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 643
- Enrollment target
NCT00784875: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00784875 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 643 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (383% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00784875, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 643 participants
- Enrollment target
Study Summary
The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
Primary Outcome
Total Sleep Time is defined as time in bed minus total time awake. Minimum would be 0; no defined maximum (except if as defined as time in bed). The higher the number, the more time asleep. Calculated in minutes from participant-reported daily sleep questionnaire averaged across study Period B (2 weeks). Change score subtracts Period B average from Period A average (baseline). Analysis of covariance (ANCOVA) Model with dependent variable being change from baseline scores and independent variable
Interventions
- DRUG Placebo
- DRUG zolpidem
- DRUG LY2624803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 643 participants |
| Start Date | 2008-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00784875 record still lists
NCT00784875 is an interventional study that assigns participants to a tested intervention. The registered 643 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (383% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00784875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00784875 about?
NCT00784875 is a clinical study titled "An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia". The purpose of this study is to compare an investigational drug (LY2624803) with placebo and with zolpidem in the treatment of outpatients with chronic insomnia.
What is the current status of trial NCT00784875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 643 participants. The study started on 2008-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00784875?
The interventions under investigation include: Placebo (DRUG), zolpidem (DRUG), LY2624803 (DRUG).
Who is sponsoring clinical trial NCT00784875?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00784875's enrollment target sits among peer trials
643 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05146297 · 644 participants · NA
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
- NCT06994442 · 644 participants · Phase 3
Optimizing Pain Treatment in Children On Mechanical Ventilation
- NCT05204888 · 642 participants · NA
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home
- NCT07012395 · 645 participants · Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia